Effect of catheter ablation in atrial fibrillation patients irrespective of their baseline heart failure: An updated meta-analysis
Abstract Introduction Patients with atrial fibrillation (AF) are associated with higher morbidity and mortality. Catheter ablation (CA) is supposed to improve outcomes in these patients. We aimed to update the evidence regarding CA in AF patients irrespective of their baseline heart failure. Methods We searched PubMed, Scopus, WOS, and Cochrane until February 2024 for relevant studies assessing the impact of CA compared to medical regimens in AF patients with and without heart failure. Outcomes of interest were all-cause mortality, cardiovascular mortality, hospitalization for HF, hospitalization for other cardiovascular causes, and stroke. Results 13 studies were included with a total of 18370 patients. In HF patients, irrespective to their ejection fraction, CA was associated with a significant reduction in all-cause mortality (RR 0.40, 95%CI [0.37 to 0.44], cardiovascular mortality (RR 0.36, 95%CI [0.32 to 0.42]), hospitalization from HF (RR 0.65, 95%CI [0.51 to 0.82]), hospitalization from other cardiovascular causes (RR 0.71, 95%CI [0.57 to 0.89]), and the incidence of stroke (RR 0.55, 95%CI [0.50 to 0.62]). Also, six studies with a total of 2015 patients compared CA to medical treatment in AF patients with HFrEF and HFpEF. CA showed a significant reduction in all-cause mortality in HFpEF patients compared to HFrEF (RR 0.46, 95%CI [0.25 to 0.85]) with no significant differences in terms of other studied outcomes. Moreover, six studies compared CA to medical treatment in HF vs no HF with a total of 2931 patients. Patients with AF and no HF had a significant reduction in all-cause mortality (RR .041, 95%CI [0.20 to 0.80]), with no significant differences in stroke or AF recurrence. Conclusion Current evidence supports the use of catheter ablation in atrial fibrillation patients, irrespective of their baseline heart failure, to achieve lower mortality and hospitalization rates.all-cause mortalitycardiovascular mortality
Authors
- Mahmoud Alkhawaldeh (ORCID: https://orcid.org/0000-0002-4717-8290)
- Ahmed Abdelaziz (ORCID: https://orcid.org/0000-0002-1257-3450)
- Avin Fadilla Helmi (ORCID: https://orcid.org/0000-0003-1785-0565)
- Ahmed Farid Gadelmawla (ORCID: https://orcid.org/0000-0002-5802-2291)
- Ahmed Elshahat (ORCID: https://orcid.org/0000-0002-6657-0458)
- Basel Abdelazeem (ORCID: https://orcid.org/0000-0002-2919-6196)
- Aida Ahmed Mohamed (ORCID: https://orcid.org/0009-0008-4691-8139)
- Mariam Desouki
- Mohamed Elbadry (ORCID: https://orcid.org/0000-0002-9020-8870)
- Raneem Afify
- A. E. Mohamed
- C J Lavie
- Doaa Mashaly (ORCID: https://orcid.org/0009-0009-4178-2874)
- L Slipczuck
Institutions
- Montefiore Medical Center (US)
- Jordan University of Science and Technology (JO)
- Tanta University (EG)
- West Virginia University Hospitals (US)
- Al-Azhar University (ID)
- University of Minnesota Medical Center (US)
- October 6 University (EG)
- Menoufia University (EG)
- Alexandria University (EG)
Publication Details
- Journal
- European Heart Journal
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1093/eurheartj/ehae666.567
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00